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ALLOGENEIC TRANSPLANTATION FOR WISKOTT ALDRICH SYNDROME
USING A REDUCED INTENSITY CONDITIONING REGIMEN
Barnes, Y.J.1, Hayashi, R.J.2, Witty, S.2, Shenoy, S.2 1St. Louis Chil-
dren’s Hospital, Saint Louis, MO; 2Washington University School of
Medicine Pediatric Hematology/Oncology, Saint Louis, MO.
Background: Allogeneic stem cell transplantation (SCT) is
curative for Wiskott Aldrich syndrome (WAS), an X-linked
disorder with thrombocytopenia, immune deﬁciency, and sus-
ceptibility to malignancy/autoimmunity. Standard myeloabla-
tive conditioning regimen for SCT often result in lasting tox-
icities. Hence, we used reduced intensity conditioning (RIT) in
2 patients whose disease manifestations included infections and
hemorrhage.
Methods: The 2 males (R1 and R2), 7 and 8 months old,
underwent SCT with bone marrow from a HLA identical sibling
and 10/10 allele matched unrelated donor respectively. Condi-
tioning consisted of 23 and 28 mg of Campath-1H (targeted
dose was 33 mg) on days -22 and -19, ﬂudarabine (1.0 mg/kg/
day) on day -8 to -4, and melphalan (4.7 mg/kg) on day -3.
GVHD prophylaxis included cyclosporine, short course meth-
otrexate, and methylprednisolone. GCSF was administered until
neutrophil engraftment.
Results: Campath-1H was associated with vasculitic edema
and blisters in R1 resulting in lowered dosing. R2 received a
lower dose following an unrelated aspiration episode. Neutro-
phils engrafted (ANC 500/dl) on days 15 and 12; platelets
engrafted (20,000/dl) on days 70 and 13 respectively. Neither
developed grade 2 GVHD or severe organ toxicity. R1 is off
immunosuppression and R2 is on a cyclosporine taper. By mo-
lecular analysis 9 months post SCT, R1 has 81% lymphoid and
22% myeloid; R2 has 100% lymphoid and 65% myeloid donor
chimerism that is stable post immunosuppression taper. R2
developed autoimmune hemolytic anemia that responded to
rituximab therapy. Neither had bleeding complications. Lym-
phocyte subpopulations and function were recovering 6 months
post SCT.
Conclusions: This reduced intensity conditioning achieved
mixed donor chimerism in 2 patients with WAS, resulting in
transfusion independence and amelioration of bleeding compli-
cations. SCT was not associated with signiﬁcant organ toxicity
or GVHD. Monitoring for durability of engraftment and other
transplant related complications is in progress. A reduced in-
tensity transplant that allows stable donor engraftment and
limits chemotherapy may spare young patients toxicities of stan-
dard conditioning and merits further investigation.
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CHARACTERISTICS OF THE PEDIATRIC BLOOD AND MARROW TRANS-
PLANT ADVANCED PRACTICE NURSE
Barnes, Y.J.1, Fisher, V.L.2, Olson, E.3, PBMTC Nursing Discipline4
1St. Louis Children’s Hospital, Saint Louis, MO; 2Rainbow Babies and
Children’s Hospital, Cleveland, OH; 3Children’s Health Care of At-
lanta, Atlanta, GA; 4Pediatric Blood and Marrow Transplant Consor-
tium Nursing Discipline.
Purpose: This survey was designed to identify the demographics
and professional responsibilities of a Pediatric Advanced Practice
Nurse (APN) in the ﬁeld of Blood & Marrow Transplantation
(BMT) within the Pediatric Blood & Marrow Transplant Consor-
tium (PBMTC).
Methods: A survey was sent to nurses within institutions that
participate in the PBMTC. The survey was designed to collect
information about personal and institutional demographics, trans-
plant speciﬁc responsibilities and procedures.
Results: Thirty-one surveys were returned representing re-
sponses from various institutions. Demographic characteristics of
the APN are reported in Table 1. All APN’s report performing
both autologus and allogeneic transplants. Eight-three percent are
individual pediatric transplant programs with 75% of them aca-
demic centers 201 beds. The majority of all centers are FACT
(Foundation of Accreditation for the Cellular Therapy) accredited,
CIBMTR reporting centers & research centers. Sixty-two percent
report an individual designated for quality assurance. Approxi-
mately half of these institutions have a designated program man-
ager. The predominant APN responsibilities include the following:
initial consults (58%), initial H & P (41%), communicate with
referring centers (74%), initial contact for complications (45%),
daily patient rounds (62%), consulted for BMT pts in PICU
(58%), and 75% are involved in clinical decision making on patient
care. The predominant APN tasks are orders pre BMT evaluation
62%, prescribes admission orders 50%, performs Bone Marrow
aspirate/biopsy 41%, lumbar punctures 33%, infuses stem cells
45%, harvest 50%, manages drug levels 62%, provides discharge
education 70%, organizes home care set up and writes discharge
orders/prescriptions 50%, & formulates post-BMT follow up plan
70%. The support staff at institutions includes 1-2 physicians
(41%), 1-2 nurse practitioners (45%), nurse coordinators (87%),
1-2 data managers (79%), and all have a search coordinator. The
median salary ranges from $70,000 -$79,000 with 87% employed
full time. Ninety-one percent of respondents identiﬁed attending
outside institutional meetings and generating research based nurs-
ing projects.
Conclusion: Based on the submitted surveys the PBMTC APN
is a highly experienced and motivated nurse who has multiple
responsibilities over the transplant trajectory. Support for this
PBMTC APN deserves further attention related to the vast re-
sponsibilities these individuals perform.
Table 1 Demographic Data
Demographics Results
Age 40 - 45 yrs
Sex Female  100%
Averge years as
RN
> 16 yrs  58%
Averge years as
APN
6 - 10 yrs  25% , >11yrs 38%
Highest degree MSN  70%
Job title Nurse Practitioner  37%, Nurse
Coordinator  41%, Clinical
Nurse Specialist  16%
Practice Area Both in-patient & outpatient care
areas  83%
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ONCE-DAILY INTRAVENOUS BUSULFAN VERSUS ORAL BUSULFAN IN
CHILDREN PRIOR TO STEM CELL TRANSPLANTATION: STUDY OF
PHARMACOKINETICS AND CLINICAL OUTCOMES
Boelens, J.J.1, Bartelink, I.2, Bredius, R.3, Zwaveling, J.4,
Bierings, M.1, Rademaker, K.2, Ververs, T.2, Kesteren, C. van2
1UMCU/WKZ: Dept. Haematology/Immunology/BMT, Utrecht,
Netherlands; 2UMCU: Dept. Clinical Pharmacy, Utrecht, Netherlands;
3LUMC: Dept. of Heamatology/Immunology/BMT, Leiden, Nether-
lands; 4LUMC: Dept. of Clinical Pharmacy, Leiden, Netherlands.
Background: Dose targeting (IV or oral) of busulfan has been
suggested to be associated with higher “alive and engrafted” (A&E)
rates due to less graft-failure and lower toxicity. Busulfan is usually
given in 4 doses. In this study we compared the outcome of
haematopoietic stem cell transplantation (SCT) between once daily
IV dose-targeted busulfan (IVdtBU: based on therapeutic drug
monitoring (TDM)) and current practice of un-targeted oral
busulfan (POBU) and we studied the feasibility of TDM of busul-
fan in clinical practice.
Methods: Since 2003 IVdtBU was introduced gradually: at ﬁrst
only in pts receiving an SCT for an “inborn error of metabolism”,
followed by immunodeﬁciency pts and malignancies. Busulfan was
part of a myeloablative regimen. Serotherapy was given in case of
an unrelated donor. Pts received a 3-hour infusion of busulfan at a
ﬁrst dose of 120mg/m2 (1year) or 80mg/m2 (1year), or POBU
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